Financial Result for the period ended 31st march 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.3 pts more than Nifty Microcap 250 and 9.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Chandra Bhagat Pharma Limited reported audited financial results for the year ended March 31, 2026. Profit before tax increased significantly to Rs 410.50 lakhs from Rs 116.54 lakhs in the prior year, representing approximately 252% growth. Operating cash flow turned positive at Rs 923.57 lakhs compared to negative Rs 570.89 lakhs previously, indicating a major improvement in cash generation. Total assets decreased from Rs 10,153.04 lakhs to Rs 9,420.58 lakhs. Short-term borrowings reduced from Rs 1,857.65 lakhs to Rs 1,393.92 lakhs. The statutory auditor issued an unmodified (clean) opinion on the financial results, and the company confirmed this via a declaration under SEBI regulations.
Strong positive signal for shareholders as profit grew over 2.5x and the company swung from negative to positive operating cash flow. The clean audit opinion removes concerns about financial reporting quality. However, rising trade receivables (from Rs 3,594.55 to Rs 5,461.70 lakhs) may warrant monitoring.